Document Detail


Clinical efficacy and tolerability of isradipine in the treatment of mild-to-moderate hypertension in young and elderly patients.
MedLine Citation:
PMID:  1376836     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
The clinical efficacy and tolerability of isradipine was evaluated in 63 patients with mild-to-moderate hypertension [supine systolic blood pressure (SBP) greater than or equal to 160 mm Hg and diastolic blood pressure (DBP) greater than or equal to 95 mm Hg]. Patients were divided into two groups according to age: group A (n = 41), aged 37-69 years (mean age of 54 +/- 7 years); group B (n = 22), aged 70-80 years (mean age of 72.8 +/- 2.4 years). After a 3-week washout period, group A received 2.5 mg of isradipine twice daily for 6 weeks. Group B received 1.25 mg of isradipine initially, increasing to 2.5 mg twice daily according to treatment response and tolerability. At the end of treatment (week 6), there were statistically significant decreases (p less than 0.01) in supine SBP and DBP in both groups compared with baseline values: the mean SBP in groups A and B decreased from 160.0 +/- 14.7 to 133.6 +/- 10.0 mm Hg and from 161.6 +/- 17.8 to 134.8 +/- 10.9 mm Hg, respectively; the mean DBP in groups A and B decreased from 101.3 +/- 3.0 to 83.6 +/- 5.5 mm Hg and from 101.3 +/- 8.4 to 84.2 +/- 3.6 mm Hg, respectively. Clinical and laboratory parameters did not change significantly during treatment. Side effects (headache, flushing, palpitations, and edema) were mild/moderate and disappeared after the first 2 weeks of treatment. In conclusion, 2.5 mg of isradipine twice daily is effective and well tolerated in the treatment of mild-to-moderate hypertension regardless of patient age.
Authors:
M Batlouni; D Armaganijan; N Ghorayeb; M F Magliano
Related Documents :
3437066 - Long-term antihypertensive effects and safety of nitrendipine in patients with mild, mo...
6749426 - Can dropout and other noncompliance be minimized in a clinical trial? report from the v...
6390696 - Comparison of the effectiveness of a beta blocker (atenolol) and a diuretic (chlorthali...
6356866 - Clinical responses to oxprenolol in the elderly.
8436016 - Effect of head position on the dynamics of the upper esophageal sphincter and pharynx.
1720526 - Impedance measurements in the human right ventricle using a new pacing system.
Publication Detail:
Type:  Clinical Trial; Comparative Study; Journal Article    
Journal Detail:
Title:  Journal of cardiovascular pharmacology     Volume:  19 Suppl 3     ISSN:  0160-2446     ISO Abbreviation:  J. Cardiovasc. Pharmacol.     Publication Date:  1992  
Date Detail:
Created Date:  1992-07-23     Completed Date:  1992-07-23     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  7902492     Medline TA:  J Cardiovasc Pharmacol     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  S53-7     Citation Subset:  IM    
Affiliation:
Dante Pazzanese Institute of Cardiology, São Paulo, Brazil.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Age Factors
Aged
Blood Pressure / drug effects
Calcium Channel Blockers / adverse effects,  therapeutic use*
Dihydropyridines / adverse effects,  therapeutic use*
Drug Tolerance
Female
Heart Rate / drug effects
Humans
Hypertension / drug therapy*
Isradipine
Male
Middle Aged
Chemical
Reg. No./Substance:
0/Calcium Channel Blockers; 0/Dihydropyridines; 75695-93-1/Isradipine

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Isradipine in the treatment of mild-to-moderate hypertension in Portugal.
Next Document:  Metabolic, hematological, and cardiac effects of long-term isradipine treatment in mild-to-moderate ...